Showing 1,521 - 1,540 results of 32,364 for search '(( 50 ((ng decrease) OR (((we decrease) OR (a decrease)))) ) OR ( e point decrease ))', query time: 0.56s Refine Results
  1. 1521
  2. 1522
  3. 1523
  4. 1524
  5. 1525
  6. 1526
  7. 1527

    Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action by Christopher J. Zerio (11595690)

    Published 2021
    “…A medicinal chemistry campaign produced the novel eIF4A inhibitor <b>28</b>, which decreased BJAB Burkitt lymphoma cell viability. …”
  8. 1528

    Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action by Christopher J. Zerio (11595690)

    Published 2021
    “…A medicinal chemistry campaign produced the novel eIF4A inhibitor <b>28</b>, which decreased BJAB Burkitt lymphoma cell viability. …”
  9. 1529
  10. 1530
  11. 1531
  12. 1532
  13. 1533
  14. 1534
  15. 1535
  16. 1536
  17. 1537

    Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar by Chemaitelly, Hiam

    Published 2023
    “…Methods and analysis We conducted a national cohort study on 312 109 Qatari citizens to investigate incidence of severe, critical or fatal COVID-19 classified according to the WHO criteria between 28 February 2020 and 21 April 2023. …”
    Get full text
    Get full text
  18. 1538
  19. 1539

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  20. 1540

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”